ConductScience.org, home

Paper36745446

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.

Meier S and 40 others. JAMA Neurol, 2023. Cited by 231 papers, by iCite.

Cite this record

ConductScience Library. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. Papers, record 36745446. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36745446

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
PubMed
Journal
JAMA Neurol
PubMed
Year
2023
PubMed
Publication types
Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
231
iCite
Relative citation ratio, by iCite
28.6
iCite
Revised in PubMed
2024-02-07
PubMed

Authors41

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Meier SStephanie
2Willemse EAJEline A J
3Schaedelin SSabine
4Oechtering JJohanna
5Lorscheider JJohannes
6Melie-Garcia LLester
7Cagol AAlessandro
8Barakovic MMuhamed
9Galbusera RRiccardo
10Subramaniam SSuvitha
11Barro CChristian
12Abdelhak AAhmed
13Thebault SSimon
14Achtnichts LLutz
15Lalive PPatrice
16Müller SStefanie
17Pot CCaroline
18Salmen AAnke
19Disanto GGiulio
20Zecca CChiara

Source PubMed

See all 41 authorsDownload CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple SclerosisMajor topic
Male
Humans
Female
Adult
Middle Aged
Cohort Studies
Glial Fibrillary Acidic Protein
Intermediate Filaments
Prospective Studies
Disease Progression
Biomarkers
Neurofilament Proteins
Recurrence

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06871072Telerehabilitation for Multiple SclerosisBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by169

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.

PMIDTitleJournalYearIn PapersSource
42975661Uncovering disability progression in people with multiple sclerosis: a practical guide.J Neurol2026https://conductscience.org/library/papers/42975661PubMed
42948123A 2-year multimodal prospective cohort study to predict sustained progression independent of relapse activity in multiple sclerosis.Front Neurol2026https://conductscience.org/library/papers/42948123PubMed
42941936Limited Gut Microbiome Differences Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Shotgun Metagenomic Study.Int J Mol Sci2026https://conductscience.org/library/papers/42941936PubMed
42911241DELPHI expert consensus-derived factors influencing the early use of monoclonal high-efficacy therapies in treatment-naïve patients with relapsing-remitting multiple sclerosis.J Neurol2026https://conductscience.org/library/papers/42911241PubMed
42904235Beyond biomarker validation: defining when serum neurofilament light chain should influence management in multiple sclerosis.Front Immunol2026https://conductscience.org/library/papers/42904235PubMed
42897668Neural stem cell transplantation in progressive multiple sclerosis: STEMS study long-term outcomes.Stem Cell Res Ther2026https://conductscience.org/library/papers/42897668PubMed
42879711Serum Glial-Related Biomarkers Show Distinct Contributions to Radiologic and Clinical Outcomes in Early Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm2026https://conductscience.org/library/papers/42879711PubMed
42819529Chimeric antigen receptor T-cell therapy in neuroimmune diseases: mechanistic rationale, clinical experience, and translational challenges.Front Immunol2026https://conductscience.org/library/papers/42819529PubMed
42814369Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies.Drugs2026https://conductscience.org/library/papers/42814369PubMed
42809446Autologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm2026https://conductscience.org/library/papers/42809446PubMed
42798289Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.Eur J Neurol2026https://conductscience.org/library/papers/42798289PubMed
42753010Impact of age, BMI, and renal function adjustment on interpretation of serum NfL and GFAP in multiple sclerosis progression: a scoping review.Neurol Sci2026https://conductscience.org/library/papers/42753010PubMed
42751212Smoldering neuroinflammation in progressive multiple sclerosis: mechanisms, imaging biomarkers, and therapeutic opportunities.Front Immunol2026https://conductscience.org/library/papers/42751212PubMed
42728304Recognition and management of acute relapse of multiple sclerosis, neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.Cell Death Differ2026https://conductscience.org/library/papers/42728304PubMed
42625502Interpreting p-tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults.Alzheimers Dement2026https://conductscience.org/library/papers/42625502PubMed
42593635Genetic Risk in Multiple Sclerosis: Susceptibility, Modifiers and Unresolved Questions.Neurol Ther2026https://conductscience.org/library/papers/42593635PubMed
42533190Comorbidities in multiple sclerosis: acquired hepatocerebral degeneration mimicking disease progression.Neurol Sci2026https://conductscience.org/library/papers/42533190PubMed
42525242Prognostic factors in paediatric-onset multiple sclerosis: a narrative review.J Neurol2026https://conductscience.org/library/papers/42525242PubMed
42512509Beyond Relapses: A Multimodal Biomarker Framework for Progression Independent of Relapse Activity and Smouldering Multiple Sclerosis.Brain Sci2026https://conductscience.org/library/papers/42512509PubMed
42459947Cross-platform comparison of blood glial fibrillary acidic protein quantification in healthy controls and multiple sclerosis.Mult Scler J Exp Transl Clin2026https://conductscience.org/library/papers/42459947PubMed

See all 169 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GFAP2670PubTator's text mininghttps://conductscience.org/library/genes/2670

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36745446

GET https://conductscience.org/api/papers/v1/36745446/authors?page=2